A microneutralization test for foot-and-mouth disease virus antibodies is described and compared to the standard mouse test.
The neutralization of foot-and-mouth disease virus (FMDV) strains in tissue cultures (2, 6) and in mice (1) has been reported. The introduction of microtitration techniques (14) has greatly facilitated similar assays in several other virus systems (3, 7-11, 13, 15) . This report describes a microneutralization (MN) assay for titration of FMDV antibodies and compares the results with those obtained in suckling mice.
The FMDV used in this investigation were: FMDV, type A, subtype 12, strain 119 (A-119); FMDV, type A, strain CANEFA-1 (A-1); FMDV, type 0, subtype 1, strain CANEFA-2 (0-2); and FMDV, type C, subtype 3, strain Rezende (C-3). All viruses were isolated from infectious bovine tongue epithelium and passaged seven to eight times in primary calf kidney cell cultures. Samples of infectious tissue culture fluids were frozen and stored at -70 C. Antisera, obtained from 30 Hereford steers used in an FMDV A-1, 0-2, and C-3 monovalent and trivalent vaccine trial, were titered by the mouse neutralization assay, and the results were reported by Graves (5) . The present study, which used the same set of antisera, provides a direct correlation between the mouse test and the MN test described.
The medium used for diluting serum, virus, and cells and for cell growth consisted of equal volumes of Eagle's minimum essential medium and Hanks balanced salt solution, the latter containing 0.5% lactalbumin hydrolysate. The medium contained 4% heat-inactivated bovine serum, 100 units of penicillin per ml, and 200 pg of streptomycin per ml. Appropriate virus dilutions for infectivity assays and serum-virus mixtures for MN assays were prepared in tubes (typically 2 ml) and incubated as necessary. Two drops from a 1-ml pipette of a cold, uniform suspension of cells containing three to five million cells/ml were added to each tube and to a diluent control. The contents of each tube were then mixed by pipetting, and 0.2-ml samples were distributed into four wells in one row of a microplate (model IS-FB-96-TC, Linbro Chemical Co. Inc., New Haven, Conn.). The plates were incubated at 37 C in a humidified atmosphere containing 5 % CO2. Virus cytopathic effect was determined microscopically, and results were recorded after 48 hr of incubation. Infectivity titers as TCID5o/ml and neutralization titers as MN50/ml were calculated by the method of Karber as described by Finney (4) . Additional virus infectivity and serum-neutralizing activity titrations were performed in suckling mice (1), as necessary for comparative purposes.
All of the cell types used regularly in this laboratory proved applicable to the procedure. a Analysis of variance was determined as follows. When the virus types were the source of variation, the degrees of freedom were 2, the sum of the squares was 1.8290, and the mean square was 0.9145. When the monovalent versus the trivalent vaccine trial was the source of variation, the degree of freedom was 1, the sum of the squares was 0.4539, and the mean square was 0.4539. When the interaction was the source of variation, the degrees of freedom were 2, the sum of the squares was 1.2055, and the mean square was 0.6027. For the residual variation, the degrees of freedom were 24, the sum of the squares was 4.0003, and the mean squarewas 0.1666. The total degrees of freedom were 29, and the sum of the squares was 7.4887. with the value of 0.1785 found by Graves (5) in similar analysis of the PD50 values for the identical sera. Thus, there are no significant differences in the 50% end points estimated by the two tests.
The correlation of the end-point titers obtained by both tests is shown in Fig. 1 
